PMID- 38094669
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231214
IS  - 1551-6776 (Print)
IS  - 2331-348X (Electronic)
IS  - 1551-6776 (Linking)
VI  - 28
IP  - 8
DP  - 2023
TI  - Characterization of Propofol Use For Non-Procedural Sedation in a Pediatric 
      Intensive Care Unit.
PG  - 714-720
LID - 10.5863/1551-6776-28.8.714 [doi]
AB  - OBJECTIVE: Given the limited literature describing propofol use in pediatric 
      patients, this study aimed to describe the dosing and duration of propofol 
      infusions for non-procedural sedation in the pediatric intensive care unit 
      (PICU). The secondary objectives were to describe the change in concomitant 
      sedative requirements from the 24-hour period before propofol initiation to the 
      24-hour period after discontinuation of propofol and to review the frequency of 
      adverse events. METHODS: This retrospective descriptive cohort study evaluated 
      children 1 month to less than 18 years old who received a continuous infusion of 
      propofol for non-procedural sedation in the PICU between May 2018 and August 
      2020. RESULTS: One hundred thirty propofol infusions representing 127 unique 
      patients (median age, 2.9 years) were included. The median (IQR) propofol 
      infusion duration was 18 (10-28) hours, and the median (IQR) average dose was 4.1 
      (2.9-5.6) mg/kg/hr. Extubation was attempted in 96 patients (74%) within 24 hours 
      of propofol infusion discontinuation. For patients that remained intubated with 
      continuous sedation, concomitant continuous opioid and midazolam requirements 
      decreased by 20% (p = 0.865) and 43% (p = 0.011), respectively. Patients 
      receiving propofol for over 24 hours experienced the largest percent decrease in 
      concomitant sedation with midazolam. There were no confirmed cases of 
      propofol-related infusion syndrome (PRIS). CONCLUSIONS: Durations and doses of 
      propofol infusions for non-procedural sedation vary widely at our institution. 
      Propofol may be beneficial as an adjunct sedative, but prospective studies are 
      needed to further explore the effect of propofol on decreasing the requirements 
      of concomitant opioids and benzodiazepines.
CI  - Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, 
      email: membership@pediatricpharmacy.org.
FAU - Bartlett, Jenna Wood
AU  - Bartlett JW
AD  - Department of Pharmacy (JB, BC, MMM), Texas Children's Hospital, Houston, TX.
FAU - Curry, Brooke N
AU  - Curry BN
AD  - Department of Pharmacy (JB, BC, MMM), Texas Children's Hospital, Houston, TX.
FAU - Musick, Matthew A
AU  - Musick MA
AD  - Department of Pediatrics (MAM), Division of Critical Care Medicine, Baylor 
      College of Medicine, Houston, TX.
FAU - Moore, Megan McKee
AU  - Moore MM
AD  - Department of Pharmacy (JB, BC, MMM), Texas Children's Hospital, Houston, TX.
LA  - eng
PT  - Journal Article
DEP - 20231212
PL  - United States
TA  - J Pediatr Pharmacol Ther
JT  - The journal of pediatric pharmacology and therapeutics : JPPT : the official 
      journal of PPAG
JID - 101089851
PMC - PMC10715379
OTO - NOTNLM
OT  - extubation
OT  - intensive care
OT  - pediatrics
OT  - propofol
OT  - propofol infusion syndrome
OT  - sedation
EDAT- 2023/12/14 06:42
MHDA- 2023/12/14 06:43
PMCR- 2023/01/01
CRDT- 2023/12/14 04:21
PHST- 2022/08/02 00:00 [received]
PHST- 2023/02/22 00:00 [accepted]
PHST- 2023/12/14 06:43 [medline]
PHST- 2023/12/14 06:42 [pubmed]
PHST- 2023/12/14 04:21 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.5863/1551-6776-28.8.714 [doi]
PST - ppublish
SO  - J Pediatr Pharmacol Ther. 2023;28(8):714-720. doi: 10.5863/1551-6776-28.8.714. 
      Epub 2023 Dec 12.